Thank you for Subscribing to Life Science Review Weekly Brief
Clinical trial patient recruitment can be difficult, but it is essential to accelerate the process so that new medicines can enter the market as soon as possible.
FREMONT, CA: One of the most challenging aspects of medical research nowadays is the speed as patients need new therapies immediately once, yet clinical studies are frequently delayed or shut down owing to a lack of individuals willing to participate.
Sponsors can meet and beat deadlines by recruiting patients for clinical trials and quickly bring novel treatments to patients. Patients worldwide seek medicines that will be better than their present options and cure their health conditions.
If the patient recruitment process for clinical trials is faster, the entire drug development process can also be done quickly. For example, a new medicine takes typically at least ten years to reach the market, with clinical trials accounting for more than half of that period (six to seven years). When that period is shortened, much-needed medicines can reach patients sooner.
It can be difficult to envision the benefits of increasing patient recruitment in a setting where even achieving stated deadlines would be a welcome shift. Here are some of the most compelling reasons to focus on accelerating patient recruiting
Save on operational cost
Running a clinical trial is a vast, enormous investment, and patient recruitment is a challenge in itself. But once patients are enrolled in a study, many people and resources are engaged in guaranteeing that the survey has appropriate sites, that the investigational medication is administered correctly, the patients are immediately
followed, and the data is securely collected. It is also necessary to ensure all procedures are followed in producing and presenting an NDA to the FDA.
Improve sponsor's reputation
Trial sponsors are frequently required to report their medical study status to boards, investors, or shareholders. One method to ensure that the sponsor maintains support for the trial and even improves their reputation in front of the key stakeholders is to speed up recruiting and enrolment.
Move on more quickly
People know that clinical studies don't always result in a successful treatment. According to a survey, the average chance of FDA approval from Phase 1 was 9.6 percent, or one in ten, and this percentage is much lower in particularly complex diseases like cancer.
Once treatment has progressed to Phase 2, the chances of advancing to Phase 3 remain low, with less than a third of investigational treatments moving to this stage. This is the nature of clinical trials, but the difficulty is that finding patients for the trials might take years and determining that an investigational treatment doesn't work as expected can take even longer.